Meeting Report: Sustaining and strengthening HIV vaccine R&D in Europe

The Global HIV Vaccine Enterprise (the Enterprise) meeting in Ghent, Belgium, provided an opportunity to engage as a region on critical issues, including political and research commitments in Europe, with the aim of ensuring that HIV vaccine R&D remains a key priority in a challenging and changing global health landscape.

Viewpoint: The complex challenges of HIV vaccine development

In this viewpoint published in The Lancet, key stakeholders look into the challenges of developing an HIV vaccine from development to marketing.